Asston Pharmaceuticals IPO

LISTED

SME

BSE • Lot Size: 1000 • SME

Issue₹123

→

Listed₹119-3%

→

Now₹84.6-31.2%

↓31.2%

*Last updated on 11 Jan 2026

Price Band

₹115 - ₹123

Lot Size

1000

Issue Size

₹27.56 Cr

GMP

N/A

Subscription

186.55x

Analyzing...

IPO Schedule

Open

9 Jul 2025

11 Jul 2025

Allotment

Listing

16 Jul 2025

About Asston Pharmaceuticals

Asston Pharmaceuticals is an SME operating in the pharmaceutical sector, likely focusing on manufacturing or distribution of specific drug formulations. The company's specific niche and product portfolio are crucial to understanding its competitive positioning.

Key Strengths

High Return on Equity (ROE) of 50.56% indicates efficient use of shareholder equity and strong profitability.
Relatively low P/E ratio of 17.83 suggests the company may be undervalued compared to its earnings, presenting a potential investment opportunity.
Operating in the pharmaceutical sector, which generally exhibits defensive characteristics and consistent demand.
SME status allows for potentially faster growth and agility compared to larger pharmaceutical corporations (though with inherently higher risk).
If the company has a strong brand recognition in its niche, it could be a significant competitive advantage.

Risk Factors

•SME IPOs are inherently riskier than mainboard IPOs due to smaller size, potentially lower liquidity, and increased susceptibility to market fluctuations.
•Dependence on regulatory approvals and compliance within the pharmaceutical industry poses significant risk. Changes in regulations can drastically impact operations and profitability.
•The specific product portfolio of Asston Pharmaceuticals is unknown, rendering an assessment of competitive pressures difficult. Reliance on a limited number of products could create vulnerability.

Valuation Analysis

While the ROE and P/E appear attractive, a thorough due diligence of the company's financial health, business model, and competitive landscape is essential before making an investment decision. The SME segment warrants extra caution and an understanding of the inherent risks.